Rheumatoid arthritis (Q57349151)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19157532 AND SRC:MED&resulttype=core&format=json

20 January 2020

title

Rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19157532 AND SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19157532 AND SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Anca Irinel Catrina

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19157532 AND SRC:MED&resulttype=core&format=json

20 January 2020

Stephen Paget

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19157532 AND SRC:MED&resulttype=core&format=json

20 January 2020

language of work or name

English

0 references

publication date

20 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19157532 AND SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19157532 AND SRC:MED&resulttype=core&format=json

20 January 2020

volume

373

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19157532 AND SRC:MED&resulttype=core&format=json

20 January 2020

issue

9664

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19157532 AND SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

659-672

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19157532 AND SRC:MED&resulttype=core&format=json

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Comorbidities in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Rheumatoid vasculitis: becoming extinct?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Use and significance of anti-CCP autoantibodies in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Perinatal characteristics and risk of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Mixed lymphocyte cultures in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Two independent alleles at 6q23 associated with risk of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Association of arthritis with a gene complex encoding C-type lectin-like receptors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis. Results from a primary care‐based incident case‐control study in Norfolk, England

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Association between occupational exposure to mineral oil and rheumatoid arthritis: results from the Swedish EIRA case-control study

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Alcohol, androgens and arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Ethanol prevents development of destructive arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Predominantly T-Cell Infiltrate in Rheumatoid Synovial Membranes

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Oral contraceptives, cigarette smoking and other factors in relation to arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Occupations and exposures in the work environment as determinants for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Risk factors for the development of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Citrullination in extra-articular manifestations of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

The presence of citrullinated proteins is not specific for rheumatoid synovial tissue

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Citrullination is an inflammation-dependent process

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Depletion of collagen II-reactive T cells and blocking of B cell activation prevents collagen II-induced arthritis in DBA/1j mice

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Cytokines in the pathogenesis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Cytokine pathways and joint inflammation in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Interleukin 6: from bench to bedside

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Is IL-1 a good therapeutic target in the treatment of arthritis?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Do self-perpetuating B lymphocytes drive human autoimmune disease?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Activated T lymphocytes support osteoclast formation in vitro

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Inflammatory response: pathway across the blood-brain barrier.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Osteoclasts are essential for TNF-alpha-mediated joint destruction

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

1 reference

7 January 2021

Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Proteinases in the joint: clinical relevance of proteinases in joint destruction

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Arterial stiffness in chronic inflammatory diseases

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Consensus statement on the use of rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

The present and future of comprehensive outcome measures for rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Conventional x-ray in early arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Does extremity-MRI improve erosion detection in severely damaged joints? A study of long-standing rheumatoid arthritis using three imaging modalities

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Ultrasonography of the metatarsophalangeal joints in rheumatoid arthritis: comparison with magnetic resonance imaging, conventional radiography, and clinical examination

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Cytokine production in culture by cells isolated from the synovial membrane

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

New therapies for treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Interindividual and intra-articular variation of proinflammatory cytokines in patients with rheumatoid arthritis: potential implications for treatment.

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Early rheumatoid arthritis: strategies for prevention and management

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Switching anti-TNF-alpha agents: what is the evidence?

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

The role of drug and disease registries in rheumatic disease epidemiology

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Infections in patients with rheumatoid arthritis treated with biologic agents

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Malignancy and biologic therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(09)60008-8

7 January 2021

10.1016/S0140-6736(09)60008-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19157532 AND SRC:MED&resulttype=core&format=json

20 January 2020

1 reference